» Articles » PMID: 22952821

Establishment of Mouse Teratocarcinomas Stem Cells Line and Screening Genes Responsible for Malignancy

Overview
Journal PLoS One
Date 2012 Sep 7
PMID 22952821
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The sequential transplantation of embryonal carcinoma cells in vivo can accelerate the growth and malignancy of teratocarcinomas. However, the possible molecular mechanisms in this process that reflect cancer formation in the early stage are largely unknown and. To identify which genes are associated with the changes of malignancy of teratocarcinomas, we established a tumorigenesis model in which teratocarcinoma were induced via injecting embryonic stem cells into immuno-deficiency mice, isolating teratocarcinoma stem cell from a teratocarcinoma in serum-free culture medium and injecting teratocarcinoma stem cells into immune-deficient mice continuously. By using high-throughput deep sequence technology, we identified 26 differentially expressed genes related to the changes of characteristics of teratocarcinoma stem cell in which 18 out of 26 genes were down-regulated and 8 genes were up-regulated. Among these genes, several tumor-related genes such as Gata3, Arnt and Tdgf1, epigenetic associated genes such as PHC1 and Uty were identified. Pathway enrichment analysis result revealed that Wnt signaling pathway, primary immunodeficiency pathway, antigen processing and presentation pathway and allograft rejection pathway were involved in the teratocarcinoma tumorigenesis (corrected p value<0.05). In summary, our study established a tumorigenesis model and proposed some candidate genes and signaling pathways that may play a key role in the early stage of cancer occurrence.

Citing Articles

Mechanisms Regulating Stemness and Differentiation in Embryonal Carcinoma Cells.

Kelly G, Gatie M Stem Cells Int. 2017; 2017:3684178.

PMID: 28373885 PMC: 5360977. DOI: 10.1155/2017/3684178.


11R-P53 and GM-CSF Expressing Oncolytic Adenovirus Target Cancer Stem Cells with Enhanced Synergistic Activity.

Lv S, Ye Z, Liu P, Huang Y, Li L, Liu H J Cancer. 2017; 8(2):199-206.

PMID: 28243324 PMC: 5327369. DOI: 10.7150/jca.16406.


Suppression of malignancy by Smad3 in mouse embryonic stem cell formed teratoma.

Li P, Chen Y, Meng X, Xiaoming M, Kwok K, Huang X Stem Cell Rev Rep. 2013; 9(5):709-20.

PMID: 23794057 DOI: 10.1007/s12015-013-9452-5.


Wnt/beta-catenin signaling in embryonic stem cell converted tumor cells.

Peng X, Liu T, Wang Y, Yan Q, Jin H, Li L J Transl Med. 2012; 10:196.

PMID: 22995718 PMC: 3515512. DOI: 10.1186/1479-5876-10-196.

References
1.
Semenza G . HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002; 8(4 Suppl):S62-7. DOI: 10.1016/s1471-4914(02)02317-1. View

2.
Lu D, Carson D . Inhibition of Wnt signaling and cancer stem cells. Oncotarget. 2011; 2(8):587. PMC: 3248212. DOI: 10.18632/oncotarget.309. View

3.
Papaioannou V, McBurney M, Gardner R, Evans M . Fate of teratocarcinoma cells injected into early mouse embryos. Nature. 1975; 258(5530):70-73. DOI: 10.1038/258070a0. View

4.
Ying Q, Nichols J, Evans E, Smith A . Changing potency by spontaneous fusion. Nature. 2002; 416(6880):545-8. DOI: 10.1038/nature729. View

5.
Chambers I, Smith A . Self-renewal of teratocarcinoma and embryonic stem cells. Oncogene. 2004; 23(43):7150-60. DOI: 10.1038/sj.onc.1207930. View